Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 120,615 shares of the medical equipment provider’s stock after purchasing an additional 14,609 shares during the period. Pictet Asset Management Holding SA owned about 0.06% of Zimmer Biomet worth $12,741,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ZBH. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $25,000. Dunhill Financial LLC lifted its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $39,000. OFI Invest Asset Management purchased a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $40,000. Finally, SRS Capital Advisors Inc. raised its position in shares of Zimmer Biomet by 146.9% during the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 285 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH opened at $112.32 on Wednesday. The company has a 50 day moving average of $107.29 and a two-hundred day moving average of $107.14. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $130.89. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market cap of $22.36 billion, a P/E ratio of 25.24, a P/E/G ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company posted $2.20 earnings per share. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ZBH shares. Stifel Nicolaus increased their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Raymond James dropped their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Barclays reduced their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Truist Financial restated a “hold” rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.